Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma.
In order to evaluate the prognostic factors for progression and survival in patients with a low tumor mass asymptomatic multiple myeloma (MM), we studied 59 patients who had a long term follow-up. Cytogenetic abnormalities (using conventional cytogenetics) were observed in 14 out of 45 analyzable patients (31%). An abnormal karyotype and a bone marrow (BM) plasmacytosis > 15% were found to be adverse prognostic factors for progression in univariate and multivariate analysis.
Depil
Stephane
S
Service des Maladies du Sang Hôpital Claude Huriez, CHU rue Michel Polonovski 59037 Lille, France.
Leleu
Xavier
X
Micol
Jean-Baptiste
JB
Berthon
Celine
C
Laï
Jean Luc
JL
Bauters
Francis
F
Quesnel
Bruno
B
Facon
Thierry
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000473:pathology*; D002869:Chromosome Aberrations; D018450:Disease Progression; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors